265 related articles for article (PubMed ID: 34740610)
1. A highly-specific fully-human antibody and CAR-T cells targeting CD66e/CEACAM5 are cytotoxic for CD66e-expressing cancer cells in vitro and in vivo.
Baek DS; Kim YJ; Vergara S; Conard A; Adams C; Calero G; Ishima R; Mellors JW; Dimitrov DS
Cancer Lett; 2022 Jan; 525():97-107. PubMed ID: 34740610
[TBL] [Abstract][Full Text] [Related]
2. Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5-SN38 Antibody-drug Conjugate in Neuroendocrine Prostate Cancer.
DeLucia DC; Cardillo TM; Ang L; Labrecque MP; Zhang A; Hopkins JE; De Sarkar N; Coleman I; da Costa RMG; Corey E; True LD; Haffner MC; Schweizer MT; Morrissey C; Nelson PS; Lee JK
Clin Cancer Res; 2021 Feb; 27(3):759-774. PubMed ID: 33199493
[TBL] [Abstract][Full Text] [Related]
3. Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer.
Lee JK; Bangayan NJ; Chai T; Smith BA; Pariva TE; Yun S; Vashisht A; Zhang Q; Park JW; Corey E; Huang J; Graeber TG; Wohlschlegel J; Witte ON
Proc Natl Acad Sci U S A; 2018 May; 115(19):E4473-E4482. PubMed ID: 29686080
[TBL] [Abstract][Full Text] [Related]
4. Chimeric antigen receptor-T cells are effective against CEACAM5 expressing non-small cell lung cancer cells resistant to antibody-drug conjugates.
Kim YJ; Li W; Zhelev DV; Mellors JW; Dimitrov DS; Baek DS
Front Oncol; 2023; 13():1124039. PubMed ID: 36923424
[TBL] [
